NAVLE Integumentary

Equine Sarcoids Study Guide

📅 March 28, 2026 ⏱ 25 min read

Equine sarcoids are the most common cutaneous neoplasm in horses, representing approximately 20% of all equine tumors and 36-40% of all equine skin tumors worldwide.

Overview and Clinical Importance

Equine sarcoids are the most common cutaneous neoplasm in horses, representing approximately 20% of all equine tumors and 36-40% of all equine skin tumors worldwide. These locally invasive fibroblastic tumors are associated with bovine papillomavirus (BPV) types 1 and 2, and while they do not metastasize, they can cause significant welfare concerns, economic losses, and functional impairment, particularly when located periocularly or in areas subject to tack contact.

Sarcoids affect horses of all breeds, ages, and sexes, though peak incidence occurs between 2-9 years of age. The condition is notoriously difficult to treat, with high recurrence rates following therapy, making early recognition and appropriate management essential clinical skills for the NAVLE examination.

Risk Level	Breeds	Notes
Highest Risk	Quarter Horses, Arabians, Appaloosas, Donkeys	Quarter Horses: 2x risk compared to Thoroughbreds; Donkeys significantly overrepresented
Moderate Risk	Thoroughbreds, Irish Sport Horses	Associated with ELA-W13 allele
Lower Risk	Standardbreds, Warmbloods	Standardbreds have lowest reported incidence among common breeds

Etiology and Pathogenesis

Bovine Papillomavirus Association

Bovine papillomavirus (BPV) types 1 and 2 (and more recently type 13) are strongly implicated in sarcoid development. BPV DNA has been detected in up to 100% of sarcoid tissue samples. Key points regarding BPV involvement include:

BPV-1 and BPV-2 are deltapapillomaviruses that cause benign fibropapillomas in cattle but induce persistent tumors in equids
The virus remains episomal (non-integrated) in equine fibroblasts, unlike productive infection in cattle
BPV E5, E6, and E7 oncoproteins drive cellular transformation, hyperproliferation, and resistance to apoptosis
Viral load correlates with disease severity - higher BPV DNA levels are associated with more aggressive sarcoid types
Unlike cattle where lesions spontaneously regress, equine sarcoids persist due to differences in immune response

High-YieldBPV DNA can be found in normal skin of sarcoid-affected horses and horses living near affected animals or cattle with papillomas. However, presence of viral DNA alone is not sufficient for sarcoid development - genetic susceptibility is also required.

Transmission and Risk Factors

The exact mode of BPV transmission to horses remains incompletely understood. Proposed mechanisms include:

Fly vectors: House flies (Musca domestica) and stable flies (Stomoxys calcitrans) may mechanically transmit BPV between animals
Fomite transmission: Contaminated tack, grooming equipment, and stable management practices
Wound contamination: Sarcoids frequently develop at sites of previous skin trauma or scarring
Contact with cattle: Horses housed near cattle with papillomas show increased sarcoid prevalence

Genetic Predisposition

Genetic susceptibility plays a critical role in sarcoid development and is linked to the equine leukocyte antigen (ELA) system (equine MHC). Specific associations include:

ELA-W13 allele: Relative risk factor of 3.0; present in high frequency in sarcoid-bearing horses
ELA-A3 allele: Relative risk factor of 2.13
Sarcoid susceptibility is heritable - familial clustering of sarcoids has been documented

Breed Predisposition

NAVLE TipRemember "QAAD" for high-risk breeds: Quarter horses, Arabians, Appaloosas, Donkeys. Standardbreds have the Safest profile (lowest risk) - both start with "S"!

Type	Clinical Appearance	Common Locations	Clinical Behavior
Occult (Flat)	Flat, circular, hairless areas with mild hyperkeratosis; may have subtle nodules	Periocular region, inner thigh, neck, axilla, groin	Mildest form; slow growing; may progress to verrucose or fibroblastic if traumatized
Verrucose (Warty)	Gray, rough, scaly, wart-like growths; variable size; may have surface ulceration	Face, axilla, groin, distal limbs	Slow growing; can progress to fibroblastic if irritated; may be extensive
Nodular Type A	Well-defined, firm, spherical subcutaneous nodules; skin moves freely over mass	Periocular region (especially eyelids), sheath, groin	Variable growth rate; covered by normal-appearing skin; may be single or multiple
Nodular Type B	Nodules with dermal involvement; skin attached to mass; may have ulceration or alopecia	Periocular, groin, inner thigh	More invasive than Type A; may invade deeper tissues
Fibroblastic	Fleshy, exophytic, ulcerated masses; resembles granulation tissue; bleeds easily	Legs (especially wounds), groin, eyelids, any wound site	Type 1: Pedunculated. Type 2: Sessile with broad invasive base. Aggressive; rapid growth; highest recurrence risk
Malevolent	Extensive, locally invasive; spreads via lymphatics; cords of tumor tissue	Can occur anywhere; often develops from other types	Rare but most aggressive; poor prognosis; may be untreatable; not truly metastatic
Mixed	Combination of two or more types in single lesion	Any location	Most common presentation; prognosis depends on most aggressive component

Clinical Classification of Sarcoid Types

Six distinct clinical types of equine sarcoids are recognized based on gross appearance and biological behavior. Understanding these types is essential as they influence treatment selection, prognosis, and recurrence risk. Many horses present with mixed types, and less aggressive forms can progress to more aggressive types, particularly following trauma or inappropriate treatment.

High-YieldFibroblastic sarcoids closely resemble exuberant granulation tissue (proud flesh). Key differentiator: sarcoids at wound sites fail to epithelialize normally and continue to grow despite standard wound care. Any chronic non-healing wound should raise suspicion for sarcoid transformation.

Exam Focus - Sarcoid Progression Mnemonic: "O-V-N-F-M" (Oh Very Nasty Fleshy Masses): Occult to Verrucose to Nodular to Fibroblastic to Malevolent represents typical progression from mildest to most aggressive forms.

Treatment	Success Rate	Best Indications	Key Considerations
Surgical Excision (Conventional)	30-50% (up to 70% recurrence)	Small, accessible tumors where wide margins achievable	Requires 2-3 cm margins; best combined with adjunctive therapy
CO2 Laser Excision	70-80%	Periocular; areas requiring hemostasis; pedunculated lesions	Seals lymphatics; vaporizes tumor cells; requires specialized equipment
Cryotherapy	70-100%	Small superficial lesions; periocular (with caution)	Double freeze-thaw cycle; may cause depigmentation; limited to smaller lesions
Cisplatin (Intralesional)	94-96% (alone); 98% with surgery	Most sarcoid types; post-surgical wound beds	Oil emulsion or biodegradable beads; 3-4 treatments at 2-week intervals; handler safety precautions
Cisplatin Electrochemotherapy	98% (4-year non-recurrence)	Accessible tumors; referral centers	Requires general anesthesia; electrical pulses increase drug uptake; excellent outcomes
5-Fluorouracil (Intralesional)	61.5%	Smaller sarcoids (less than 13.5 cm³)	50 mg/cm³ tissue; every 2 weeks for up to 7 treatments; less expensive than cisplatin
BCG Immunotherapy	59-100% (periocular)	Periocular sarcoids; nodular types; small to medium lesions	Intralesional injection; stimulates cell-mediated immunity; risk of anaphylaxis; less effective on limbs
Imiquimod 5% Cream	60%	Flat, superficial sarcoids; occult types	Topical immunomodulator; every other day for 32 weeks; prolonged treatment course
AW4-LUDES / Topical Chemotherapy	35-80%	Various types; NOT periocular due to risk	Contains 5-FU, heavy metals, thiouracil; caustic; veterinary application only; expect inflammation
Brachytherapy (Iridium-192)	95% (periocular)	Periocular lesions; referral centers	Interstitial radiation; excellent periocular results; limited availability; radiation exposure to personnel
Ligation/Banding	Variable	Pedunculated lesions with defined neck	Rubber band or elasticized suture; tumor falls off in 10-14 days; combine with topical therapy

Diagnosis

Clinical Diagnosis

Diagnosis is often made based on clinical appearance, particularly when multiple lesions of characteristic types are present. Studies show that visual examination by experienced clinicians corresponds to histologic diagnosis in approximately 82% of cases. However, accuracy varies with experience level, and sarcoids can be confused with other conditions.

Differential Diagnoses

Fibroma/fibrosarcoma
Neurofibroma
Squamous cell carcinoma
Exuberant granulation tissue (proud flesh)
Papilloma (warts)
Melanoma (in gray horses)
Eosinophilic/collagenolytic granuloma
Dermatophytosis (ringworm) - for early occult sarcoids

Histopathology

Histopathological examination provides definitive diagnosis but should be approached cautiously. Biopsy carries risk of tumor exacerbation - surgical trauma may activate latent BPV and stimulate more aggressive regrowth.

Characteristic Histologic Features

Increased density of dermal fibroblasts: The minimum criterion for diagnosis; arranged in whorls, streams, and/or bundles
Rete peg formation: Epidermal extensions projecting into the dermal tumor mass
Picket fence arrangement: Fibroblasts oriented perpendicular to the epidermal basement membrane
Epidermal hyperplasia and hyperkeratosis: Particularly in verrucose and mixed types
BPV DNA detection: PCR testing confirms presence of BPV-1 or BPV-2 DNA

NAVLE TipNAVLE commonly tests the concept that biopsy of suspected sarcoids carries risk of tumor exacerbation. If biopsy is performed, excisional biopsy is preferred over incisional, and the owner should be counseled about the need for definitive treatment if histopathology confirms sarcoid. Benign neglect after partial biopsy is NOT recommended.

Prognostic Histologic Indicators

Recent studies have identified histologic features that may predict recurrence following surgical excision:

Mitotic count: Sarcoids with mitotic count of 20 or more per 2.37 mm² have significantly higher recurrence rates (80%) compared to lower mitotic counts (18%)
Clinical type: Fibroblastic sarcoids are significantly more likely to recur than verrucous, mixed, or nodular types

Favorable Prognostic Factors	Poor Prognostic Factors
Single lesion Small tumor size Occult or verrucose type No previous treatment Low mitotic count (less than 10/2.37 mm²) Non-periocular location Early intervention	Multiple lesions Large tumor size (greater than 13.5 cm³) Fibroblastic or malevolent type Previous failed treatment High mitotic count (20 or more/2.37 mm²) Periocular or limb location Incomplete excision margins

Treatment

There is no universally effective treatment for equine sarcoids. Treatment selection depends on sarcoid type, size, location, number of lesions, previous treatments, patient factors, and available resources. Key principles include:

Early treatment of smaller, less aggressive tumors yields better outcomes
Multimodal approaches often more successful than single-modality treatment
Failed treatment can result in more aggressive recurrence
Horses with multiple lesions have lower treatment success rates

Treatment Modalities and Success Rates

High-YieldCisplatin electrochemotherapy has the highest documented success rate (98%) but requires referral. For general practice, intralesional cisplatin combined with surgical excision provides excellent results (94-98%). BCG immunotherapy remains a good option for periocular sarcoids (up to 100% success in some studies) where surgical options are limited.

NAVLE TipBenign neglect is rarely appropriate for sarcoids. In a study of 42 untreated periocular lesions, ALL eventually required treatment, and 64% of horses were euthanized because lesions became too extensive. Early treatment improves outcomes.

Prognosis and Recurrence

Prognosis varies significantly based on multiple factors:

Key Points on Recurrence:

Recurrence rates range from 2-80% depending on treatment modality and tumor factors
Most recurrences occur within 6 months of treatment
Recurrent tumors are often more aggressive than original lesions
Genetic susceptibility means treated horses remain at risk for new sarcoid development throughout life
Spontaneous regression is rare but has been documented

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →